1-855-378-42281-855-378-4228
One of the out-patient treatment options for people in Emden who are struggling with opioid dependence and addiction is called opioid maintenance therapy. Licensed facilities and doctors are authorized to give specific medications to opioid addicted people, many of which are opioid-based themselves and are habit forming. With low amounts however, the client doesn't experience being high and also doesn't experience intense cravings and is not experiencing opioid withdrawal. Methadone is the first drug used for this reason, but there are alternative choices currently to pick from.
Methadone is an opiate and is meant to be taken at an outpatient medical center certified to administer the drug, which is taken on a daily basis in liquid or pill form. The cost of the drug is around under $200 per month. Buprenorphine is also an opioid based med, and is a pill often taken every other day. But unlike Methadone that can only be dispensed in well-regulated medical centers, Buprenorphine can be and is prescribed and administered in doctor's offices. The cost monthly of buprenorphine is around just under $300 monthly for the generic version of the drug. There is also a type of buprenorphine containing the drug naloxone, which is a drug which blocks the effects of opioids. Someone taking this version of the drug, also known as Suboxone, would find it harder to feel high from opioids if they relapsed while taking the drug. It is also taken on a daily basis, and costs around $450 a month. Naltrexone is an additional medication used in opioid maintenance therapy, but unlike the other drugs mentioned here it is an opioid blocker and is not an opioid. A person has the choice to take this drug as a monthly injection, and that is called Vivitrol. As an opioid blocker, it prevents someone from experience being high from opioids, and therefore lowers the risk associated with relapse. This daily injection costs anywhere from $1000 to $1200 monthly.
For All Drug and Alcohol Rehab Centers In Emden, Click Here.
